Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INDP | Indaptus Therapeutics, Inc.

Index- P/E- EPS (ttm)-1.75 Insider Own2.30% Shs Outstand8.40M Perf Week-19.82%
Market Cap21.25M Forward P/E- EPS next Y-1.88 Insider Trans134.28% Shs Float5.76M Perf Month4.23%
Income-14.60M PEG- EPS next Q-0.55 Inst Own6.90% Short Float / Ratio0.39% / 1.14 Perf Quarter41.88%
Sales- P/S- EPS this Y8.00% Inst Trans13.90% Short Interest0.02M Perf Half Y49.72%
Book/sh2.22 P/B1.22 EPS next Y2.10% ROA-57.10% Target Price8.00 Perf Year-2.17%
Cash/sh2.51 P/C1.08 EPS next 5Y- ROE-63.60% 52W Range1.25 - 4.08 Perf YTD86.90%
Dividend- P/FCF- EPS past 5Y57.90% ROI- 52W High-33.58% Beta1.17
Dividend %- Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low116.80% ATR0.28
Employees6 Current Ratio9.40 Sales Q/Q- Oper. Margin- RSI (14)45.13 Volatility13.82% 8.73%
OptionableNo Debt/Eq0.00 EPS Q/Q16.80% Profit Margin- Rel Volume2.23 Prev Close3.33
ShortableYes LT Debt/Eq0.00 EarningsAug 14 BMO Payout- Avg Volume19.79K Price2.71
Recom2.00 SMA20-10.97% SMA5010.65% SMA20034.98% Volume44,072 Change-18.62%
Sep-19-23 08:00AM
Sep-06-23 08:05AM
Aug-14-23 08:00AM
Aug-10-23 08:45AM
Aug-07-23 08:00AM
08:00AM Loading…
Jun-15-23 08:00AM
May-31-23 08:30AM
May-11-23 07:00AM
May-09-23 08:00AM
May-01-23 08:00AM
Apr-24-23 09:00AM
Apr-20-23 04:05PM
Apr-19-23 09:28AM
Apr-17-23 08:00AM
08:00AM Loading…
Mar-22-23 08:00AM
Mar-17-23 08:00AM
Mar-15-23 08:05AM
Mar-13-23 08:05AM
Mar-07-23 08:05AM
Feb-14-23 08:00AM
Feb-07-23 08:05AM
Dec-13-22 07:30AM
Nov-10-22 04:05PM
Oct-18-22 07:00AM
Sep-06-22 09:02AM
Aug-08-22 08:00AM
Jun-09-22 07:00AM
Jun-03-22 07:00AM
May-23-22 08:00AM
07:00AM Loading…
May-19-22 07:00AM
May-18-22 04:15PM
May-12-22 08:00AM
May-03-22 12:20PM
Apr-20-22 07:00AM
Mar-23-22 07:00AM
Mar-21-22 07:00AM
Mar-17-22 07:00AM
Mar-07-22 07:00AM
Jan-14-22 09:38AM
Jan-05-22 07:00AM
Jan-03-22 07:00AM
Dec-01-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 10:51AM
Sep-15-21 07:00AM
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Glen R.10% OwnerAug 14Buy2.3423,93456,0061,190,400Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 11Buy2.1235,06474,3361,166,466Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 10Buy1.9444,35486,0471,131,402Aug 16 06:01 PM
Litchev Boyan VesselinovChief Medical OfficerDec 01Buy1.875009351,150Dec 19 09:06 PM
Litchev Boyan VesselinovChief Medical OfficerNov 22Buy1.83500915650Dec 19 09:06 PM
Meckler Jeffrey ACEO and DirectorNov 21Buy1.909,60018,24075,374Nov 22 08:00 AM
Meckler Jeffrey ACEO and DirectorNov 18Buy1.7640070565,774Nov 22 08:00 AM